NRG-GY033 – Temporarily Closed

A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor

For more information about this clinical trial, click here

Schema & Eligibility NRG-GY033

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
Saint Mary’s Hospital, Centralia, IL
OSF Saint Anthony Health Center, Alton, IL
Mercy Hospital, St. Louis, MO
Mercy South, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mercy Hospital, Fort Smith, AK
Mercy Hospital, Joplin, MO
Mercy Clinic Cancer & Hematology, Rolla, MO
Mosaic Life Care, St. Joseph, MO
Central Care Cancer Center, Bolivar, MO
Central Care Cancer Center, Great Bend, KS
Central Care Cancer Center, Garden City, KS
Lake Regional Hospital, Osage Beach, MO

Ask your physician about participating in this clinical trial or call us.